How Will The Spinal Muscular Atrophy Market Reach $6.53 Billion By 2029 Amid Global Shifts?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Current Size And Growth Outlook For The Spinal Muscular Atrophy Market?
The size of the spinal muscular atrophy market has been rapidly expanding in the past few years. The expected growth is from $3.53 billion in 2024 to around $4 billion in 2025, with a compound annual growth rate (CAGR) of 13.3%. This significant growth in the historical period is due to factors such as enhanced diagnosis and earlier detection, a rising occurrence of rare genetic diseases, advancements in healthcare infrastructure, government and regulatory backing, and an increase in unaddressed healthcare needs.
Anticipations are high for a swift expansion in the spinal muscular atrophy market in the upcoming years. The market is predicted to escalate to a value of $6.53 billion by 2029, with a compound annual growth rate (CAGR) of 13.0%. The enhancement during the projected period can be accredited to the proliferation in awareness and diagnosis, enlarged accessibility to treatment, ramped up health expenditure into rare diseases, a supportive regulatory landscape, and escalated healthcare expenditure. The major forecast period trends include progression in orally administered treatments, embracement of gene therapy, technological progression within drug delivery systems, the employment of artificial intelligence within the evolution of SMA treatments, and gene manipulation technologies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp
What Growth-Enabling Forces Are Impacting The Spinal Muscular Atrophy Market?
The escalating occurrence of rare genetic disorders is predicted to catalyze the expansion of the spinal muscular atrophy market in the future. These disorders are the result of gene mutations which impact a minor portion of the population, often leading to severe, long-lasting health issues. The amplified occurrence of rare genetic diseases is tied to enhanced diagnostic methods, heightened awareness, and increased access to genetic testing, thereby resulting in more instances being detected and reported. Spinal muscular atrophy (SMA) is a distinct rare genetic condition that epitomizes the difficulties and potential of comprehending inherited illnesses. It underscores the significance of progressing research into genetic disorders. For example, in July 2023, as per a report published by the Office for National Statistics, a UK-based government department, genetic testing of SMN1 has allowed for meticulous epidemiological studies, disclosing that SMA transpires in 1 out of 10,000 to 20,000 live births and over 95% of the impacted patients are homozygous for SMN1 deletion. Hence, the escalating occurrence of rare genetic disorders is projected to propel the growth of the spinal muscular atrophy market.
How Does The Spinal Muscular Atrophy Market Differ By Segment?
The spinal muscular atrophymarket covered in this report is segmented –
1) By Type: Type 1 (Severe); Type 2 (Intermediate); Type 3 (Mild); Type 4 (Adult)
2) By Age: Pediatric; Adults
3) By Treatment: Drug Therapy; Gene Therapy
4) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy
Subsegments:
1) By Type 1 (Severe): Infantile-Onset SMA; Severe Progressive SMA
2) By Type 2 (Intermediate): Early-Onset SMA; Non-progressive SMA
3) By Type 3 (Mild): Juvenile-Onset SMA; Mild Progressive SMA
4) By Type 4 (Adult): Adult-Onset SMA; Late-Onset SMA
What Are The Dominant Trends Currently Seen In The Spinal Muscular Atrophy Market?
Leading companies involved in the spinal muscular atrophy market are focusing on creating novel products like dry syrup, aimed at improving patient compliance and simplifying administration for pediatric populations and other patients who find swallowing hard. Dry syrup is a medication format that involves powder which is mixed with water prior to its use, usually prescribed to children and individuals who struggle with the ingestion of pills or capsules. For example, in September 2024, Chugai Pharmaceutical Co., Ltd., hailing from Japan, officially declared the receipt of regulatory acceptance from Japan’s Ministry of Health, Labour and Welfare to broaden the indication of their drug Evrysdi (risdiplam). This allowance facilitates its use in treating pre-symptomatic spinal muscular atrophy (SMA) and further enables dosage in infants younger than two months. This achievement is crucial as it allows treatments to commence before any symptoms even emerge, which potentially increases therapy results in affected children. The decision was verified by findings from the RAINBOWFISH study, which tested Evrysdi’s safety and effectiveness in babies diagnosed with SMA but not yet exhibiting symptoms. The results demonstrated treated infants accomplished developmental milestones like unaided sitting and enhanced motor abilities by their first year, highlighting the drug’s potential to alter the course of the disease when administered at an early stage.
Who Are The Most Influential Companies In The Spinal Muscular Atrophy Market?
Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report
Which Region Is Leading Innovation In The Spinal Muscular Atrophy Market?
North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp
Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Market 2025, By The Business Research Company
Optic Atrophy Management Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report
Spinal Surgery Devices And Equipment Global Market Report 2025
Cerebrospinal Fluid Management Csf Devices And Equipment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
